Proof of principle of imaging the polyamine concentration with 7 Tesla 1H-MR spectroscopic imaging in patients with prostate cancer
ID
Source
Brief title
Condition
- Renal and urinary tract neoplasms benign
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Obtain proof of principle of the imaging of the polyamine concentration in
patients with prostate cancer, using 1H-MR spectroscopic imaging at 7T.
Secondary outcome
Study the concentration ratios of polyamines relative to creatine, choline and
citrate that occur in prostate tumors and healthy parts of the prostate.
Background summary
Escalation of the radiation dose to the prostate has been shown to benefit the
outcome of radiotherapy for patients with prostate cancer, especially for
aggressive tumors. It seems there is a correlation between the total required
radiation dose and the prostate cancer Gleason score, which is related to tumor
differentiation. To facilitate radiotherapy treatment planning, imaging is
required to localize these aggressive tumor areas in the prostate. Several MRI
techniques can be used to estimate aggressiveness, but there is a search for
better imaging parameters. The spectroscopic imaging of polyamines seems
promising. Polyamines are thought to be inversely correlated with Gleason
score. On a regular MRI (up to 3 Tesla) the poor spectral resolution limits the
capacity to image these polyamines. This study will investigate whether
polyamines can be measured on a 7 Tesla MRI.
Study objective
Proof of principle of imaging the polyamine concentration with 7 Tesla 1H-MR
spectroscopic imaging in patients with prostate cancer
Study design
Observational study.
Study burden and risks
Patients will undergo an MRI scan at the 7T MRI scanner. The scan will be
scheduled in combination with a regular appointment.
The use of an endorectal coil for MRI of the prostate is common practice. This
endorectal coil causes mild discomfort, but no risks have ever been described.
For the patients included in the study there is no individual benefit.
Heidelberglaan 100
3584 CX Utrecht
NL
Heidelberglaan 100
3584 CX Utrecht
NL
Listed location countries
Age
Inclusion criteria
prostate cancer
scheduled for a radiotherapy treatment
Exclusion criteria
Patient who meet the UMC Utrech 7T MRS exlusion criteria
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL32058.041.10 |